Table 1.

Characteristics of the patients

All patients (N = 120), n (%)EGFR mutation (n = 92), n (%)EGFR amplification (n = 88), n (%)EGFR expression (n = 75), n (%)
Age (median, 61 y)
    <6053 (44.2)44 (47.8)43 (48.9)37 (49.3)
    ≥6067 (55.8)48 (52.2)45 (51.1)38 (50.7)
Sex
    Male76 (63.3)57 (61.9)54 (61.4)47 (62.7)
    Female44 (36.7)35 (38.1)34 (38.6)28 (37.3)
Stage
    IIIB15 (12.5)8 (8.7)7 (8.0)7 (9.3)
    IV105 (87.5)84 (91.3)81 (92.0)68 (90.7)
Histology
    Adenocarcinoma74 (61.7)57 (62.0)56 (63.6)47 (62.7)
        Others46 (38.3)35 (38.0)32 (36.4)28 (37.3)
        Squamous cell31 (25.8)24 (26.1)21 (23.9)18 (24.0)
        Large cell7 (5.8)5 (5.4)5 (5.7)5 (6.7)
        Non-small cell8 (6.7)6 (6.5)6 (6.8)5 (6.7)
ECOG performance status
    0-1106 (88.3)84 (91.3)80 (90.9)67 (89.3)
    2-314 (11.7)8 (8.7)8 (9.1)8 (10.7)
Smoking
    Never smoker47 (39.2)38 (41.3)37 (42.0)44 (58.7)
    Smoker73 (60.8)54 (58.7)51 (58.0)31 (41.3)
Erlotinib
    First line19 (15.8)14 (15.2)14 (15.9)8 (10.7)
    ≥Second line101 (84.2)78 (84.8)74 (84.1)67 (89.3)
Skin rash
    Yes93 (77.5)72 (78.3)69 (78.4)59 (78.7.0)
    No27 (22.5)20 (21.7)19 (21.6)16 (21.3)
  • Abbreviation: ECOG, Eastern Cooperative Oncology Group.